MarketPulse

Eli Lilly

10 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Can Eli Lilly Become First $2T Healthcare Giant? Three Growth Catalysts in Focus

Eli Lilly eyes $2 trillion valuation from weight-loss drugs, Alzheimer's breakthroughs, and AI-powered R&D following recent market pullback.
PFENVDALLYREGNhealthcare stocksweight loss drugs
BenzingaBenzinga··Prnewswire

Eli Lilly Declares $1.73 Q2 2026 Dividend, Signaling Confidence in Pipeline

Eli Lilly declares $1.73 per-share Q2 2026 dividend payable June 10, reflecting strong financial footing and cash generation capability.
LLYdividendshareholder returns
BenzingaBenzinga··Caroline Ryan

Sirius XM Eyes iHeartMedia Merger as M&A Wave Sweeps Across Sectors

Sirius XM explores iHeartMedia acquisition while Uber buys FlyTaxi and Sun Pharma completes $11.75B Organon deal. Multiple bankruptcies filed.
LLYUBERSIRIOGNIHRT+1acquisitionsM&A
GlobeNewswire Inc.GlobeNewswire Inc.··Nxera Pharma

Nxera Pharma Posts Strong Q1 2026 as Spinoff Centessa Fetches $7.8B Lilly Deal

Nxera Pharma reported JPY 11.3B Q1 revenue driven by R&D milestones. Spinoff Centessa agreed to $7.8B acquisition by Eli Lilly.
ABBVLLYCNTANBIXrevenue growthdrug discovery
The Motley FoolThe Motley Fool··Rich Smith

Eli Lilly Slides Despite UBS Backing: $7B CAR-T Bet Divides Markets

Eli Lilly stock fell 2.5% after announcing a $7 billion acquisition of Kelonia Therapeutics for CAR-T cancer therapy, despite positive analyst rating.
LLYcancer treatmentGLP-1 drugs
GlobeNewswire Inc.GlobeNewswire Inc.··Not Specified

Nxera Pharma Hits Second Eli Lilly Milestone in Metabolic Disease Push

Nxera Pharma achieves second milestone with Eli Lilly validating its GPCR-targeting platform. Deal includes $694M in potential payments plus royalties.
LLYdiabetesdrug discovery
BenzingaBenzinga··Caroline Ryan

Wave of Mega Deals Reshape Food, Pharma Sectors Amid QVC Bankruptcy Concerns

McCormick merges with Unilever Foods for $29.1B while Sysco acquires Jetro for $29B; QVC explores bankruptcy amid retail distress.
AMZNLLYQXOQXOpBSYY+10Syscofood distribution
The Motley FoolThe Motley Fool··Adria Cimino

Beyond Weight Loss: Eli Lilly Bets Billions on AI to Power Next Generation of Blockbusters

Eli Lilly bets on AI-driven drug discovery alongside its $11B weight loss drug franchise, partnering with Nvidia and Insilico Medicine to build next-generation blockbusters.
NVDALLYartificial intelligenceweight loss drugs
BenzingaBenzinga··Vandana Singh

Eli Lilly's Eczema Drug Clears Phase 3 Pediatric Hurdle, Eyes Label Expansion

Eli Lilly's Ebglyss shows strong efficacy in pediatric atopic dermatitis trial, with 63% achieving significant skin clearance. Company plans regulatory submission for label update.
LLYFDA approvalPhase 3 trial
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Eli Lilly's Pharma Dominance: Why $LLY Attracts Long-Term Wealth Builders

$LLY dominates diabetes and weight management markets while diversifying into oncology and AI, positioning itself as a compelling long-term wealth-building investment within diversified portfolios.
NVDALLYlong-term investingdividend reinvestment